CDK5 and central nervous system cancer: In addition to inhibiting CDK7, SNS-032 also inhibits the cyclin-dependent kinases CDK2, CDK5 and CDK9 [113], however, even though SNS-032 can alter glioma response to hypoxia, it is not toxic toward U87 cells even at very high drug concentrations (500 nM) [114].